Update on the risk of lymphoma following immunosuppressive therapy for inflammatory bowel disease

References

• Engels EA, Biggar RJ, Hall HI et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int. J. Cancer123(1), 187–194 (2008).
   PubMed Web of Science ®Google Scholar
• Mbulaiteye SM, Biggar RJ, Goedert JJ, Engels EA. Immune deficiency and risk for malignancy among persons with AIDS. J. Acquir. Immune Defic. Syndr.32(5), 527–533 (2003).
   PubMed Web of Science ®Google Scholar
• Biggar RJ, Chaturvedi AK, Goedert JJ, Engels EA, HIV/AIDS Cancer Match Study. AIDS-related cancer and severity of immunosuppression in persons with AIDS. J. Natl Cancer Inst.99(12), 962–972 (2007).
   PubMed Web of Science ®Google Scholar
• Kamel OW, van de Rijn M, Weiss LM et al. Brief report: reversible lymphomas associated with Epstein–Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N. Engl. J. Med.328(18), 1317–1321 (1993).
   PubMed Web of Science ®Google Scholar
• Nalesnik MA, Jaffe R, Starzl TE et al. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am. J. Pathol.133(1), 173–192 (1988).
   PubMed Web of Science ®Google Scholar
• Paul C, Le Tourneau A, Cayuela JM et al. Epstein–Barr virus-associated lymphoproliferative disease during methotrexate therapy for psoriasis. Arch. Dermatol.133(7), 867–871 (1997).
   PubMedGoogle Scholar
• Pietersma F, Piriou E, van Baarle D. Immune surveillance of EBV-infected B cells and the development of non-Hodgkin lymphomas in immunocompromised patients. Leuk. Lymphoma49(6), 1028–1041 (2008).
   PubMed Web of Science ®Google Scholar
• Dantal J, Pohanka E. Malignancies in renal transplantation: an unmet medical need. Nephrol. Dial. Transplant.22(Suppl. 1), i4–i10 (2007).
   PubMedGoogle Scholar
• Buell JF, Gross TG, Woodle ES. Malignancy after transplantation. Transplantation80(2 Suppl.), S254–S264 (2005).
   PubMed Web of Science ®Google Scholar
• Bachman TR, Sawitzke AD, Perkins SL, Ward JH, Cannon GW. Methotrexate-associated lymphoma in patients with rheumatoid arthritis: report of two cases. Arthritis Rheum.39(2), 325–329 (1996).
   PubMed Web of Science ®Google Scholar
• Liote F, Pertuiset E, Cochand-Priollet B et al. Methotrexate related B lymphoproliferative disease in a patient with rheumatoid arthritis. Role of Epstein–Barr virus infection. J. Rheumatol.22(6), 1174–1178 (1995).
   PubMed Web of Science ®Google Scholar
• Hoshida Y, Xu JX, Fujita S et al. Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. J. Rheumatol.34(2), 322–331 (2007).
   PubMed Web of Science ®Google Scholar
• Salloum E, Cooper DL, Howe G et al. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. J. Clin. Oncol.14(6), 1943–1949 (1996).
   PubMed Web of Science ®Google Scholar
• Viraben R, Brousse P, Lamant L. Reversible cutaneous lymphoma occurring during methotrexate therapy. Br. J. Dermatol.135(1), 116–118 (1996).
   PubMed Web of Science ®Google Scholar
• Dantal J, Hourmant M, Cantarovich D et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet351(9103), 623–628 (1998).
   PubMed Web of Science ®Google Scholar
• Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am. J. Transplant.4(2), 222–230 (2004).
   PubMed Web of Science ®Google Scholar
• Gutierrez-Dalmau A, Campistol JM. Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review. Drugs67(8), 1167–1198 (2007).
   PubMed Web of Science ®Google Scholar
• Guba M, Graeb C, Jauch KW, Geissler EK. Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation. Transplantation77(12), 1777–1782 (2004).
   PubMed Web of Science ®Google Scholar
• Herman M, Weinstein T, Korzets A et al. Effect of cyclosporin A on DNA repair and cancer incidence in kidney transplant recipients. J. Lab. Clin. Med.137(1), 14–20 (2001).
   PubMed Web of Science ®Google Scholar
• Starzl TE, Nalesnik MA, Porter KA et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet1(8377), 583–587 (1984).
   PubMed Web of Science ®Google Scholar
• Zijlmans JM, van Rijthoven AW, Kluin PM, Jiwa NM, Dijkmans BA, Kluin-Nelemans JC. Epstein–Barr virus-associated lymphoma in a patient with rheumatoid arthritis treated with cyclosporine. N. Engl. J. Med.326(20), 1363 (1992).
   PubMed Web of Science ®Google Scholar
• Watabe H, Soma Y, Obara W et al. Adult T-cell lymphoma/leukaemia developing in a patient with psoriasis treated with long-term cyclosporine. Acta Derm. Venereol.86(2), 184–185 (2006).
   PubMedGoogle Scholar
• Lelievre JD, Sacre K, Adle-Biassette H, Molinier-Frenkel V, Gaulard P, Papo T. Epstein–Barr virus-associated lymphoproliferative disease after long-standing cyclosporine therapy for psoriasis: a case of spontaneous regression. J. Am. Acad. Dermatol.52(2 Suppl. 1), 24–27 (2005).
   PubMed Web of Science ®Google Scholar
• Corazza M, Zampino MR, Montanari A, Altieri E, Virgili A. Primary cutaneous CD30+ large T-cell lymphoma in a patient with psoriasis treated with cyclosporine. Dermatology206(4), 330–333 (2003).
   PubMedGoogle Scholar
• Mahe E, Descamps V, Grossin M, Fraitag S, Crickx B. CD30+ T-cell lymphoma in a patient with psoriasis treated with ciclosporin and infliximab. Br. J. Dermatol.149(1), 170–173 (2003).
   PubMedGoogle Scholar
• Cockburn IT, Krupp P. The risk of neoplasms in patients treated with cyclosporine A. J. Autoimmun.2(5), 723–731 (1989).
   PubMed Web of Science ®Google Scholar
• Birkeland SA, Hamilton-Dutoit S. Is posttransplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per se? Transplantation76(6), 984–988 (2003).
   PubMed Web of Science ®Google Scholar
• Paul CF, Ho VC, McGeown C et al. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J. Invest. Dermatol.120(2), 211–216 (2003).
   PubMed Web of Science ®Google Scholar
• Hannuksela-Svahn A, Pukkala E, Laara E, Poikolainen K, Karvonen J. Psoriasis, its treatment, and cancer in a cohort of Finnish patients. J. Invest. Dermatol.114(3), 587–590 (2000).
   PubMed Web of Science ®Google Scholar
• Farrell RJ, Ang Y, Kileen P et al. Increased incidence of non-Hodgkin’s lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low. Gut47(4), 514–519 (2000).
   PubMed Web of Science ®Google Scholar
• Shibahara T, Miyazaki K, Sato D et al. Rectal malignant lymphoma complicating ulcerative colitis treated with long-term cyclosporine A. J. Gastroenterol. Hepatol.21(1 Pt 2), 336–338 (2006).
   PubMed Web of Science ®Google Scholar
• Schwartz LK, Kim MK, Coleman M, Lichtiger S, Chadburn A, Scherl E. Case report: lymphoma arising in an ileal pouch anal anastomosis after immunomodulatory therapy for inflammatory bowel disease. Clin. Gastroenterol. Hepatol.4(8), 1030–1034 (2006).
   PubMed Web of Science ®Google Scholar
• Ellman MH, Hurwitz H, Thomas C, Kozloff M. Lymphoma developing in a patient with rheumatoid arthritis taking low dose weekly methotrexate. J. Rheumatol.18(11), 1741–1743 (1991).
   PubMed Web of Science ®Google Scholar
• Kingsmore SF, Hall BD, Allen NB, Rice JR, Caldwell DS. Association of methotrexate, rheumatoid arthritis and lymphoma: report of 2 cases and literature review. J. Rheumatol.19(9), 1462–1465 (1992).
   PubMed Web of Science ®Google Scholar
• Thomason RW, Craig FE, Banks PM, Sears DL, Myerson GE, Gulley ML. Epstein–Barr virus and lymphoproliferation in methotrexate-treated rheumatoid arthritis. Mod. Pathol.9(3), 261–266 (1996).
   PubMed Web of Science ®Google Scholar
• Ebeo CT, Girish MR, Byrd RP, Roy TM, Mehta JB. Methotrexate-induced pulmonary lymphoma. Chest123(6), 2150–2153 (2003).
   PubMedGoogle Scholar
• Suzuki M, Hirano S, Ito H et al. Pulmonary lymphoma developed during long-term methotrexate therapy for psoriasis. Respirology12(5), 774–776 (2007).
   PubMed Web of Science ®Google Scholar
• Khopkar U, Bhor U. Hodgkin’s lymphoma in a patient of psoriasis treated with long-term, low-dose methotrexate therapy. Indian J. Dermatol. Venereol. Leprol.74(4), 379–382 (2008).
   PubMed Web of Science ®Google Scholar
• Gridley G, McLaughlin JK, Ekbom A et al. Incidence of cancer among patients with rheumatoid arthritis. J. Natl. Cancer Inst.85(4), 307–311 (1993).
   PubMed Web of Science ®Google Scholar
• Hakulinen T, Isomaki H, Knekt P. Rheumatoid arthritis and cancer studies based on linking nationwide registries in Finland. Am. J. Med.78(1A), 29–32 (1985).
   PubMed Web of Science ®Google Scholar
• Isomaki HA, Hakulinen T, Joutsenlahti U. Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. J. Chronic Dis.31(11), 691–696 (1978).
   PubMedGoogle Scholar
• Prior P. Cancer and rheumatoid arthritis: epidemiologic considerations. Am. J. Med.78(1A), 15–21 (1985).
   PubMed Web of Science ®Google Scholar
• Silman AJ, Petrie J, Hazleman B, Evans SJ. Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study. Ann. Rheum. Dis.47(12), 988–992 (1988).
   PubMed Web of Science ®Google Scholar
• Symmons DP. Neoplasms of the immune system in rheumatoid arthritis. Am. J. Med.78(1A), 22–28 (1985).
   PubMed Web of Science ®Google Scholar
• Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum.50(6), 1740–1751 (2004).
   PubMed Web of Science ®Google Scholar
• Santana V, Rose NR. Neoplastic lymphoproliferation in autoimmune disease: an updated review. Clin. Immunol. Immunopathol.63(3), 205–213 (1992).
   PubMedGoogle Scholar
• Stern RS, Zierler S, Parrish JA. Methotrexate used for psoriasis and the risk of noncutaneous or cutaneous malignancy. Cancer50(5), 869–872 (1982).
   PubMed Web of Science ®Google Scholar
• Stern RS. Lymphoma risk in psoriasis: results of the PUVA follow-up study. Arch. Dermatol.142(9), 1132–1135 (2006).
   PubMedGoogle Scholar
• Bernatsky S, Clarke AE, Suissa S. Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis. Arch. Intern. Med.168(4), 378–381 (2008).
   PubMed Web of Science ®Google Scholar
• Buchbinder R, Barber M, Heuzenroeder L et al. Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum.59(6), 794–799 (2008).
   PubMed Web of Science ®Google Scholar
• Salliot C, van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann. Rheum. Dis.68(7), 1100–1104 (2009).
   PubMed Web of Science ®Google Scholar
• Tiede I, Fritz G, Strand S et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J. Clin. Invest.111(8), 1133–1145 (2003).
   PubMed Web of Science ®Google Scholar
• Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann. Intern. Med.111(8), 641–649 (1989).
   PubMed Web of Science ®Google Scholar
• Connell WR, Kamm MA, Dickson M, Balkwill AM, Ritchie JK, Lennard-Jones JE. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet343(8908), 1249–1252 (1994).
   PubMed Web of Science ®Google Scholar
• George J, Present DH, Pou R, Bodian C, Rubin PH. The long-term outcome of ulcerative colitis treated with 6-mercaptopurine. Am. J. Gastroenterol.91(9), 1711–1714 (1996).
   PubMed Web of Science ®Google Scholar
• Bouhnik Y, Lemann M, Mary JY et al. Long-term follow-up of patients with Crohn’s disease treated with azathioprine or 6-mercaptopurine. Lancet347(8996), 215–219 (1996).
   PubMed Web of Science ®Google Scholar
• Korelitz BI, Mirsky FJ, Fleisher MR, Warman JI, Wisch N, Gleim GW. Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine. Am. J. Gastroenterol.94(11), 3248–3253 (1999).
   PubMed Web of Science ®Google Scholar
• Fraser AG, Orchard TR, Robinson EM, Jewell DP. Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine. Aliment. Pharmacol. Ther.16(7), 1225–1232 (2002).
   PubMed Web of Science ®Google Scholar
• Glazier KD, Palance AL, Griffel LH, Das KM. The ten-year single-center experience with 6-mercaptopurine in the treatment of inflammatory bowel disease. J. Clin. Gastroenterol.39(1), 21–26 (2005).
   PubMed Web of Science ®Google Scholar
• Lewis JD, Bilker WB, Brensinger C, Deren JJ, Vaughn DJ, Strom BL. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology121(5), 1080–1087 (2001).
   PubMed Web of Science ®Google Scholar
• Armstrong RG, West J, Card TR. Risk of cancer in inflammatory bowel disease treated with azathioprine: a UK population-based case–control study. Am. J. Gastroenterol. (2010) (Epub ahead of print).
   Google Scholar
• Beaugerie L, Brousse N, Bouvier AM et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet374(9701), 1617–1625 (2009).
   PubMed Web of Science ®Google Scholar
• Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut54(8), 1121–1125 (2005).
   PubMed Web of Science ®Google Scholar
• Masunaga Y, Ohno K, Ogawa R, Hashiguchi M, Echizen H, Ogata H. Meta-analysis of risk of malignancy with immunosuppressive drugs in inflammatory bowel disease. Ann. Pharmacother.41(1), 21–28 (2007).
   PubMed Web of Science ®Google Scholar
• Dayharsh GA, Loftus EV Jr, Sandborn WJ et al. Epstein–Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology122(1), 72–77 (2002).
   PubMed Web of Science ®Google Scholar
• Bewtra M, Lichtenstein GR. Infliximab use in Crohn’s disease. Expert Opin. Biol. Ther.5(4), 589–599 (2005).
   PubMed Web of Science ®Google Scholar
• Cohen RD, Tsang JF, Hanauer SB. Infliximab in Crohn’s disease: first anniversary clinical experience. Am. J. Gastroenterol.95(12), 3469–3477 (2000).
   PubMed Web of Science ®Google Scholar
• Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn WJ. Infliximab for Crohn’s disease in clinical practice at the Mayo Clinic: the first 100 patients. Am. J. Gastroenterol.96(3), 722–729 (2001).
   PubMed Web of Science ®Google Scholar
• Seiderer J, Goke B, Ochsenkuhn T. Safety aspects of infliximab in inflammatory bowel disease patients. A retrospective cohort study in 100 patients of a German University Hospital. Digestion70(1), 3–9 (2004).
   PubMedGoogle Scholar
• Wenzl HH, Reinisch W, Jahnel J et al. Austrian infliximab experience in Crohn’s disease: a nationwide cooperative study with long-term follow-up. Eur. J. Gastroenterol. Hepatol.16(8), 767–773 (2004).
   PubMedGoogle Scholar
• Sands BE, Anderson FH, Bernstein CN et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N. Engl. J. Med.350(9), 876–885 (2004).
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med.353(23), 2462–2476 (2005).
   PubMed Web of Science ®Google Scholar
• Caspersen S, Elkjaer M, Riis L et al. Infliximab for inflammatory bowel disease in Denmark 1999–2005: clinical outcome and follow-up evaluation of malignancy and mortality. Clin. Gastroenterol. Hepatol.6(11), 1212–1217; quiz 1176 (2008).
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Cohen R, Feagan BG et al. Safety of infliximab and other Crohn’s disease therapies: TREAT™ registry data with 24,575 patient-years of follow-up. Am. J. Gastroenterol.103(S1), (2008).
   Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet359(9317), 1541–1549 (2002).
   PubMed Web of Science ®Google Scholar
• Ljung T, Karlen P, Schmidt D et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut53(6), 849–853 (2004).
   PubMed Web of Science ®Google Scholar
• Colombel JF, Loftus EV Jr, Tremaine WJ et al. The safety profile of infliximab in patients with Crohn’s disease: the Mayo clinic experience in 500 patients. Gastroenterology126(1), 19–31 (2004).
   PubMed Web of Science ®Google Scholar
• Lees CW, Ali AI, Thompson AI et al. The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up. Aliment. Pharmacol. Ther.29(3), 286–297 (2009).
   PubMed Web of Science ®Google Scholar
• Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum.46(12), 3151–3158 (2002).
   PubMed Web of Science ®Google Scholar
• FDA Board Document. Update on the TNF-α blocking agents; 2003 (2009).
   Google Scholar
• Khanna D, McMahon M, Furst DE. Safety of tumour necrosis factor-α antagonists. Drug Saf.27(5), 307–324 (2004).
   PubMed Web of Science ®Google Scholar
• Mikuls TR, Weaver AL. Lessons learned in the use of tumor necrosis factor-α inhibitors in the treatment of rheumatoid arthritis. Curr. Rheumatol. Rep.5(4), 270–277 (2003).
   PubMedGoogle Scholar
• Scheinfeld N. A comprehensive review and evaluation of the side effects of the tumor necrosis factor α blockers etanercept, infliximab and adalimumab. J. Dermatolog. Treat.15(5), 280–294 (2004).
   PubMedGoogle Scholar
• Schiff MH, Burmester GR, Kent JD et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann. Rheum. Dis.65(7), 889–894 (2006).
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Sandborn WJ, Rutgeerts P et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology130(2), 323–333 (2006).
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Rutgeerts P et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology132(1), 52–65 (2007).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Stoinov S et al. Certolizumab pegol for the treatment of Crohn’s disease. N. Engl. J. Med.357(3), 228–238 (2007).
   PubMed Web of Science ®Google Scholar
• Rosh JR, Lerer T, Markowitz J et al. Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn’s disease. Am. J. Gastroenterol.104(12), 3042–3049 (2009).
   PubMed Web of Science ®Google Scholar
• Humira® Injection Prescribing Information and Medication Guide. Abbot Laboratories, IL, USA (2009).
   Google Scholar
• Schreiber S, Rutgeerts P, Fedorak RN et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn’s disease. Gastroenterology129(3), 807–818 (2005).
   PubMed Web of Science ®Google Scholar
• Schreiber S, Khaliq-Kareemi M, Lawrance IC et al. Maintenance therapy with certolizumab pegol for Crohn’s disease. N. Engl. J. Med.357(3), 239–250 (2007).
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Deltenre P, de Suray N et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn’s disease: meta-analysis of placebo-controlled trials. Clin. Gastroenterol. Hepatol.6(6), 644–653 (2008).
   PubMed Web of Science ®Google Scholar
• Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn’s disease: a meta-analysis. Clin. Gastroenterol. Hepatol.7(8), 874–881 (2009).
   PubMed Web of Science ®Google Scholar
• Targan SR, Feagan BG, Fedorak RN et al. Natalizumab for the treatment of active Crohn’s disease: results of the ENCORE Trial. Gastroenterology132(5), 1672–1683 (2007).
   PubMed Web of Science ®Google Scholar
• Schweikert A, Kremer M, Ringel F et al. Primary central nervous system lymphoma in a patient treated with natalizumab. Ann. Neurol.66(3), 403–406 (2009).
   PubMed Web of Science ®Google Scholar
• Khan WA, Yu L, Eisenbrey AB et al. Hepatosplenic γ/δ T-cell lymphoma in immunocompromised patients. Report of two cases and review of literature. Am. J. Clin. Pathol.116(1), 41–50 (2001).
   PubMed Web of Science ®Google Scholar
• Ochenrider MG, Patterson DJ, Aboulafia DM. Hepatosplenic T-cell lymphoma in a young man with Crohn’s disease: case report and literature review. Clin. Lymphoma Myeloma Leuk.10(2), 144–148 (2010).
   PubMed Web of Science ®Google Scholar
• Mackey AC, Green L, Leptak C, Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update. J. Pediatr. Gastroenterol. Nutr.48(3), 386–388 (2009).
   PubMed Web of Science ®Google Scholar
• Mackey AC, Green L, Liang LC, Dinndorf P, Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr.44(2), 265–267 (2007).
   PubMed Web of Science ®Google Scholar
• Thayu M, Markowitz JE, Mamula P, Russo PA, Muinos WI, Baldassano RN. Hepatosplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn disease. J. Pediatr. Gastroenterol. Nutr.40(2), 220–222 (2005).
   PubMed Web of Science ®Google Scholar
• Zeidan A, Sham R, Shapiro J, Baratta A, Kouides P. Hepatosplenic T-cell lymphoma in a patient with Crohn’s disease who received infliximab therapy. Leuk. Lymphoma48(7), 1410–1413 (2007).
   PubMed Web of Science ®Google Scholar
• Humphreys MR, Cino M, Quirt I, Barth D, Kukreti V. Long-term survival in two patients with hepatosplenic T cell lymphoma treated with interferon-α. Leuk. Lymphoma49(7), 1420–1423 (2008).
   PubMed Web of Science ®Google Scholar
• Lewis JD, Gelfand JM, Troxel AB et al. Immunosuppressant medications and mortality in inflammatory bowel disease. Am. J. Gastroenterol.103(6), 1428–1435; quiz 1436 (2008).
   PubMed Web of Science ®Google Scholar
• Siegel CA, Hur C, Korzenik JR, Gazelle GS, Sands BE. Risks and benefits of infliximab for the treatment of Crohn’s disease. Clin. Gastroenterol. Hepatol.4(8), 1017–1024 (2006).
   PubMed Web of Science ®Google Scholar
• Lewis JD, Schwartz JS, Lichtenstein GR. Azathioprine for maintenance of remission in Crohn’s disease: benefits outweigh the risk of lymphoma. Gastroenterology118(6), 1018–1024 (2000).
   PubMed Web of Science ®Google Scholar
• Johnson FR, Ozdemir S, Mansfield C et al. Crohn’s disease patients’ risk-benefit preferences: serious adverse event risks versus treatment efficacy. Gastroenterology133(3), 769–779 (2007).
   PubMed Web of Science ®Google Scholar
• Toruner M, Loftus EV Jr, Harmsen WS et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology134(4), 929–936 (2008).
   PubMed Web of Science ®Google Scholar
• Van Assche G, Magdelaine-Beuzelin C, D’Haens G et al. Withdrawal of immunosuppression in Crohn’s disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology134(7), 1861–1868 (2008).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Rutgeerts PJ, Reinisch W et al. One year data from the SONIC study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn’s disease naive to immunomodulators and biologic therapy. Presented at: Digestive Disease Week 2009. 30 May–4 June 2009, Chicago, IL, USA (Abstract 751f).
   Google Scholar